Earlier this week a US CDC panel of advisers voted 13-1 to recommend new Covid vaccine boosters for all people over 6 months of age, contradicting European and WHO guidelines that focus on high-risk groups.
A marketing campaign accompanied the US decision. Dr. Ashish Jha, previous White House Covid coordinator, claimed that the new booster shot will help those jabbed stay in school or work, slow transmission to Grandma, and prevent long Covid, calling the decision “a no-brainer”. A press conference with senior Canadian public health authorities, socially distanced with masks, also promoted the new universal booster recommendation.
In contrast, Florida Governor Ron DeSantis and state Surgeon General Joseph Ladapo came under fire from Politico, the Washington Post and others for contradicting the new CDC and FDA’s universal recommendation. Ladapo claimed that “with the amount of immunity that’s in the community […] and with the questions we have about safety and about effectiveness”, the vaccine would not be “a good decision for young people and for people who are not at high risk at this point in the pandemic”.
Yet DeSantis’s stance echoes those from other countries, such as the UK and Sweden, that have recently removed universal recommendations for the 2023-24 season for those under 65 years old. Eligibility extends to being in a clinical risk group, being a frontline healthcare worker or a household contact of a high-risk person.
While Covid vaccine mandates have largely been removed in the US, they continue in an estimated 7% of US universities, as well as some healthcare facilities and workplaces. Universal recommendations may provide justification for maintaining or expanding them this autumn.
The new Pfizer and Moderna mRNA vaccines are formulated to the XBB.1.5 Omicron variant, a decision made back in June by the FDA. However recent US data shows that only 3% of infections are now from this particular variant (although over 50% remain from the XBB-lineage), so it is unclear how effective the new booster will really be. A report this year by the UK Health Security Agency (UKHSA) estimated an overall 37% vaccine effectiveness rate for the previous bivalent Covid booster, dropping to 20% by month four. However, this analysis was not stratified by risk group or by age.
The question of annual Covid shots is far from settled, given that the effectiveness of flu vaccines in preventing mortality and hospitalisations continues to be debated. A CDC study from the 2021-22 winter season found that the flu vaccine “did not reduce the risk for outpatient respiratory illness”.
Join the discussion
Join like minded readers that support our journalism by becoming a paid subscriber
To join the discussion in the comments, become a paid subscriber.
Join like minded readers that support our journalism, read unlimited articles and enjoy other subscriber-only benefits.
Subscribe